Close Menu
    What's Hot

    Morrisons Retirement Saver Plan Completes Bulk Purchase Annuity Buy-In With Aviva

    28 May 2025

    Yellow Pages Limited Purchases Group Annuity Contracts From BMO Life Assurance Company

    22 May 2025

    Life ILS Conference 2025

    20 May 2025
    Facebook X (Twitter) Instagram
    Instagram LinkedIn X (Twitter)
    Life Risk News
    • Home
    • Features

      New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

      14 May 2025

      Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

      14 May 2025

      Is Servicing an Overlooked Source of Life Settlement Alpha?

      14 May 2025

      Q&A: Shelly Beard, Managing Director, WTW

      14 May 2025

      Longevity Tech to Emerge as Distinct Sub-Sector of Venture Capital Market?

      14 May 2025
    • Commentary

      UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

      14 May 2025

      The Power of Uncorrelated Diversification During Market Volatility

      14 May 2025

      Overseeing BPA Growth Safely

      14 May 2025

      Could Climate Change Cause the Buy-In Market To Collapse?

      10 April 2025

      ICS vs Solvency II: Comparing Risk Corrections for Illiquid Liabilities

      10 April 2025
    • Events
    • Magazine
    • News

      Morrisons Retirement Saver Plan Completes Bulk Purchase Annuity Buy-In With Aviva

      28 May 2025

      Yellow Pages Limited Purchases Group Annuity Contracts From BMO Life Assurance Company

      22 May 2025

      Andrew Limited Pension and Life Assurance Plan Completes Bulk Annuity Transaction With Aviva

      15 May 2025

      Life Insurance Settlement Association Publishes Latest Market Data Collection Survey Results

      13 May 2025

      UK Aggregate Defined Benefit Pension Fund Surplus Down Again in April

      12 May 2025
    Subscribe
    Life Risk News
    Home » Weight Loss Drugs the Talk of the Town in Actuarial Circles

    Weight Loss Drugs the Talk of the Town in Actuarial Circles

    Features 12 February 2025Greg WintertonBy Greg Winterton
    Twitter LinkedIn Email
    Share
    Twitter LinkedIn Email

    Google recently published its list of terms most searched for in 2024, one unsurprisingly dominated by sport, with football’s Copa America and the UEFA European Championship occupying the top two spots, followed by cricket’s ICC Men’s T20 World Cup. 

    What will also not be a surprise to those in the health and mortality industries is that Ozempic saw a 35% increase in searching in 2024, with 13 million searches per month, according to Glimpse; the power of social media is widely attributed to be behind the explosion of awareness of what was originally approved as a diabetes drug, as numerous celebrities touted the weight loss benefits of these drugs. 

    And glucagon-like peptide 1 receptor agonists (GLP-1RAs) were also the talk of the town last year in the UK’s life and health insurance and pension circles. 

    “Actuaries advising insurance companies and pension schemes on mortality are paying very close attention to developments with anti-obesity medicines,” said Stuart McDonald, Partner at Lane, Clark & Peacock. 

    More than one in four adult Brits were living with obesity in 2022 and a study by Frontier Economics published in the same year suggested that the current annual full cost of obesity in the UK is an estimated £58bn.  

    Anti-obesity medicines (AOMs) including Semaglutide (branded as Wegovy or Ozempic) and Tirzepatide (branded as Mounjaro) are available on the NHS for eligible patients (broadly, those with a body mass index (BMI) of greater than 35 and a weight-related comorbidity) as well as privately; a recent article in the Financial Times suggests that up to half a million Brits have already taken the plunge privately. 

    And, while the cohort of lives involved in bulk purchase annuity deals in the UK tend to have slightly longer life expectancies (they are healthier and wealthier on average), than the median scheme member, the higher average income is exactly why usage of these drugs could continue to see strong take-up.  

    “Pension scheme liabilities are typically dominated by a relatively small number of individuals with large pensions. Such individuals, where they might benefit from AOMs, are unlikely to find the cost of a private prescription prohibitive,” said McDonald. 

    A recent study conducted in the US found numerous other benefits of taking GLP-1RAs – the type of drug that brand names Ozempic and Wegovy are based on – and found that “compared to usual care, GLP-1RA use was associated with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions”. 

    Obesity is linked to a wide range of health conditions, including cardiovascular disease, so the study results could have an even more pronounced impact on mortality. It is a welcome development in an area that, according to Nicky Draper, Director of Longevity Consulting at Crystallise, has seen slower progress in recent years. 

    “We witnessed remarkable gains in mortality improvements in the 1980s and 1990s through to the 2000s largely due to the management of cardiovascular disease, (CVD), such as the wider application of statins, improved surgical techniques, and reductions in smoking rates. It is thought that 60% of these gains were lifestyle driven, the remaining 40% from management of CVD. But then, things plateaued, because we achieved all we could with those specific interventions, and smoking rates are reducing at a much slower rate,” she said. 

    “The wider application of GLP-1RAs may well lead to an inflection point, not only in terms of cardiovascular disease, but in other indications. The ability of these drugs to tackle all parts of the metabolic pathway could have a hugely positive impact on population mortality.” 

    Indeed, just at the end of January, the US Food and Drug Administration (FDA) approved Ozempic for use in the fight against kidney disease, the third time the FDA has approved Ozempic for a specific reason (the first two being diabetes in 2017 and then cardiovascular disease in 2020). 

    “What started as a drug to help manage diabetes now seemingly has multiple applications. Sometimes, these things do come around by chance and the recent approval by the FDA for Ozempic’s use to combat kidney disease is another encouraging development for population health,” said Draper. 

    It is not all good, of course. The research also showed that there was “an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis”. 

    And last summer, the World Health Organization published a product alert relating to three falsified batches of semaglutide, and the internet is awash with nay-sayers who caution against the use of these products. 

    In drug terms, we are still in the early days of understanding the micro and macro impacts of GLP-1RAs. And it will be many years until those in the medical and science industries do. 

    So, it is almost a given that numerous other studies will be conducted in numerous countries that analyse the pros and cons of GLP-1RAs, but the current thinking is that the impact on mortality – and consequently, the pricing of transactions in the bulk purchase annuity market and the reinsurance market – could be profound given that there would be both primary and secondary impacts of these drugs. 

    “I’d expect the uptake of AOMs to continue to increase rapidly around the world, to the point where they become the biggest selling drugs of all time; the widespread adoption of AOMs seems likely to directly reduce mortality rates from a significant number of causes of death,” said McDonald.  

    “But also, a reduced prevalence of obesity among the population could also be expected to reduce pressure on the health system, which in turn improves health and mortality outcomes.” 

    2025 - February Health Longevity and Mortality Trends Mortality Risk Volume 4 Issue 2 - February 2025
    Share. Twitter LinkedIn Email

    Related Posts

    New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

    14 May 2025

    Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

    14 May 2025

    Is Servicing an Overlooked Source of Life Settlement Alpha?

    14 May 2025

    Q&A: Shelly Beard, Managing Director, WTW

    14 May 2025

    Comments are closed.

    Most Popular

    New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

    14 May 2025

    Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

    14 May 2025

    Is Servicing an Overlooked Source of Life Settlement Alpha?

    14 May 2025

    UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

    14 May 2025
    Ad

    Your trusted source for capital markets participation in Life Risk

    X (Twitter) Instagram LinkedIn
    Life Risk
    • About Life Risk News
    • Get In Touch
    • Our Team
    • Copyright Notice
    • Terms and Conditions
    • Privacy Policy
    • Sitemap
    Coverage
    • Home
    • Features
    • Events
    • Commentary
    Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT